COVID-19疫苗相关腋窝淋巴结病的消退时间及相关因素
这项回顾性单中心研究纳入111例在mRNA COVID-19疫苗接种后8周内乳腺超声检出同侧腋窝淋巴结病的患者,随访至淋巴结消退。初始超声皮质厚度平均4.7±1.2 mm,淋巴结病在初始超声后平均97±44天消退。接种辉瑞-BioNTech(而非Moderna)疫苗与更短消退时间独立相关,初始超声后接种第二剂及初始超声皮质厚度更大与更长消退时间独立相关。
要点
- mRNA疫苗接种后乳腺超声检出的腋窝淋巴结病消退时间较长,平均在初始超声后97±44天。
- 初始超声皮质厚度平均4.7±1.2 mm,厚度越大消退时间越长。
- 接种辉瑞-BioNTech疫苗者消退时间较短,初始超声后接种第二剂者消退时间较长。
核心结论
- COVID-19 mRNA疫苗接种后乳腺超声检出的腋窝淋巴结病持续时间长于初始疫苗临床试验报告。
研究设计与样本
- 回顾性单中心研究,纳入111例(平均年龄52±12岁)在mRNA COVID-19疫苗接种后8周内乳腺超声检出同侧腋窝淋巴结病、并以4至12周间隔随访超声至淋巴结消退的患者;从医疗记录提取信息,回顾性测量超声上最大腋窝淋巴结皮质厚度(大于3 mm视为增大),采用多变量线性回归分析识别消退时间的独立预测因素。
关键影像表现/征象
- 初始超声上最大腋窝淋巴结皮质厚度平均为4.7±1.2 mm。
- 淋巴结病在初始超声检查后平均97±44天消退,在首剂疫苗接种后平均127±43天消退,平均经过2.4±0.6次随访超声检查。
诊断标准与关键数值
- 超声上最大腋窝淋巴结皮质厚度大于3 mm视为增大。
- 辉瑞-BioNTech(而非Moderna)疫苗接种是更短消退时间的显著独立预测因素(β = -18.0 [95% CI, -34.3 to -1.7];p = .03)。
- 初始超声检查后接种第二剂是更长消退时间的显著独立预测因素(β = 19.2 [95% CI, 3.1-35.2];p = .02)。
- 初始超声检查时皮质厚度更大是更长消退时间的显著独立预测因素(β = 8.0 [95% CI, 1.5-14.5];p = .02)。
- 患者年龄、乳腺癌病史和腋窝症状与消退时间无显著关联(所有p > .05)。
临床应用与阅片要点
- 延长的消退时间支持不因近期COVID-19疫苗接种而推迟筛查乳腺X线摄影。
- 延长的消退时间也支持专业学会的建议:怀疑疫苗相关淋巴结病时随访间隔至少12周。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. The variable clinical course of subclinical lymphadenopathy detected on breast imaging after COVID-19 vaccination creates management challenges and has led to evolving practice recommendations. OBJECTIVE. The purpose of this study was to assess the duration of axillary lymphadenopathy ipsilateral to COVID-19 vaccination detected by breast imaging and to assess factors associated with the time until resolution. METHODS. This retrospective single-center study included 111 patients (mean age, 52 ± 12 years) with unilateral axillary lymphadenopathy ipsilateral to mRNA COVID-19 vaccine administration performed within the prior 8 weeks that was detected on breast ultrasound performed between January 1, 2021, and October 1, 2021, and who underwent follow-up ultrasound examinations at 4- to 12-week intervals until resolution of the lymphadenopathy. Patient information was extracted from medical records. Cortical thickness of the largest axillary lymph node on ultrasound was retrospectively measured and was considered enlarged when greater than 3 mm. Multivariable linear regression analysis was used to identify independent predictors of time until resolution. RESULTS. The mean cortical thickness at the initial ultrasound examination was 4.7 ± 1.2 mm. The lymphadenopathy resolved a mean of 97 ± 44 days after the initial ultrasound examination, 127 ± 43 days after the first vaccine dose, and 2.4 ± 0.6 follow-up ultrasound examinations. A significant independent predictor of shorter time to resolution was Pfizer-BioNTech (rather than Moderna) vaccination (β = -18.0 [95% CI, -34.3 to -1.7]; p = .03]. Significant independent predictors of longer time to resolution were receipt of the second dose after the initial ultrasound examination (β = 19.2 [95% CI, 3.1-35.2]; p = .02) and greater cortical thickness at the initial ultrasound examination (β = 8.0 [95% CI, 1.5-14.5]; p = .02). Patient age, history of breast cancer, and axillary symptoms were not significantly associated with time to resolution (all p > .05). CONCLUSION. Axillary lymphadenopathy detected with breast ultrasound after COVID-19 mRNA vaccination lasts longer than reported in initial vaccine clinical trials. CLINICAL IMPACT. The prolonged time to resolution supports not delaying screening mammography because of recent COVID-19 vaccination. It also supports the professional society recommendation of a follow-up interval of at least 12 weeks when vaccine-related lymphadenopathy is suspected.
引用
- Lane, Eisen, Drotman, et al. Time for Resolution of COVID-19 Vaccine-Related Axillary Lymphadenopathy and Associated Factors. AJR Am J Roentgenol. 2022. PMID: 35583425. doi:10.2214/AJR.22.27687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。